scholarly journals In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria

2007 ◽  
Vol 60 (3) ◽  
pp. 575-581 ◽  
Author(s):  
Marion Grare ◽  
Maxime Mourer ◽  
Stéphane Fontanay ◽  
Jean-Bernard Regnouf-de-Vains ◽  
Chantal Finance ◽  
...  
2006 ◽  
Vol 50 (6) ◽  
pp. 2261-2264 ◽  
Author(s):  
Hee-Soo Park ◽  
Hyun-Joo Kim ◽  
Min-Jung Seol ◽  
Dong-Rack Choi ◽  
Eung-Chil Choi ◽  
...  

ABSTRACT DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.


2010 ◽  
Vol 54 (9) ◽  
pp. 3974-3977 ◽  
Author(s):  
Michelle M. Butler ◽  
John D. Williams ◽  
Norton P. Peet ◽  
Donald T. Moir ◽  
Rekha G. Panchal ◽  
...  

ABSTRACT Antimicrobial susceptibilities of 233 Gram-positive and 180 Gram-negative strains to two novel bis-indoles were evaluated. Both compounds were potent inhibitors of Gram-positive bacteria, with MIC90 values of 0.004 to 0.5 μg/ml. One bis-indole, MBX 1162, exhibited potent activity against all Gram-negative strains, with MIC90 values of 0.12 to 4 μg/ml, even against high-level-resistant pathogens, and compared favorably to all comparator antibiotics. The bis-indole compounds show promise for the treatment of multidrug-resistant clinical pathogens.


2005 ◽  
Vol 49 (8) ◽  
pp. 3501-3512 ◽  
Author(s):  
Helio S. Sader ◽  
Thomas R. Fritsche ◽  
Koné Kaniga ◽  
Yigong Ge ◽  
Ronald N. Jones

ABSTRACT PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.


Author(s):  
Meredith A. Hackel ◽  
James A. Karlowsky ◽  
Michele A. Canino ◽  
Daniel F. Sahm ◽  
Nicole E. Scangarella-Oman

Gepotidacin (formerly GSK2140944) is a first in class triazaacenaphthylene antibacterial currently in Phase III clinical trials. When tested against Gram-negative ( n =333) and Gram-positive ( n =225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates (MIC 90 ) at concentrations of 4 and 2 μg/ml, respectively. Given gepotidacin’s in vitro activity against the anaerobic isolates tested, further study is warranted to better understand gepotidacin’s utility in the treatment of infections caused by clinically relevant anaerobic organisms.


2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  

Chemotherapy ◽  
2007 ◽  
Vol 54 (1) ◽  
pp. 43-49 ◽  
Author(s):  
S. Roveta ◽  
A. Marchese ◽  
E.A. Debbia

Sign in / Sign up

Export Citation Format

Share Document